Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|November 12, 2015
On-line Analyzer Measures Water Bioburden
Mettler Toledo Thornton’s 7000RMS delivers on-line, real-time, continuous measurement of microbes and inert particles in purified pharmaceutical waters.
Mettler Toledo Thornton’s 7000RMS (Real-time Microbial System) delivers on-line, real-time, continuous measurement of microbes and inert particles in purified pharmaceutical waters. On-line monitoring of conductivity and total organic carbon is well established, but determining microbial contamination has almost entirely relied on laboratory measurement of cultures. The time taken to grow cultures, and the multiple testing of points-of-use, results in many days of delay in identifying microbial excursions. The new technology will help companies validate water systems in real time, reduce off-line sampling costs and help eliminate false-positive tests.
The compact unit provides real-time assessment of water-loop bioburden levels, lowers labor costs via reduced sampling and testing, reduces energy use through better management of sanitization cycles, and leads to increased process understanding and product safety. Unlike other modern techniques for measuring microbes in water, the laser-induced fluorescence (LIF) technology employed in the 7000RMS does not require time-consuming staining or use of reagents. The implementation of LIF in the analyzer, in conjunction with Mie scattering detection and advanced software algorithms, allows the simultaneous measurement of particle numbers and determination of whether particles are microbes or inert material. The analyzer is suitable for on-line and at-line use and for laboratory measurements of grab samples.
Source:
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.